Comprehensive GLP-1 Receptor Agonist Market Insights: Forecasting Size, Growth, and Competitive Trends from 2025 to 2034

Which drivers are expected to have the greatest impact on the over the glp-1 receptor agonist market's growth?
The GLP-1 receptor agonist market is forecasted to grow, driven by the increasing incidence of diabetes. This chronic disease occurs when the pancreas is unable to produce enough insulin or the body fails to effectively use the insulin it generates. Diabetes mellitus, characterized by elevated blood sugar levels, is a metabolic disorder that can be managed with GLP-1 receptor agonist i.e it encourages the body to generate more insulin, subsequently reducing blood sugar. Hence, the growth of the diabetes epidemic predicts an expansion of the GLP-1 receptor agonist market. To illustrate, records from the UK's Office for Health Improvement and Disparities in March 2024 showed that from March 2022 to March 2023, there was a 22% increase in the number of individuals with type 1 diabetes who received all eight recommended care processes. Similarly, for type 2 diabetes, there was a 21% increase. Furthermore, the percentage of individuals meeting the target HbA1c levels reached an all-time high of 37.9% according to the National Diabetes Audit (NDA). As such, the expanding incidence of diabetes is fuelling the growth of the GLP-1 receptor agonist market.

Get Your GLP-1 Receptor Agonist Market Report Here:
https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report

What is the future CAGR of the glp-1 receptor agonist market, and how will it impact industry expansion?
The market size of the GLP-1 receptor agonist has seen a consistent increase in recent years. The projected growth is from $13.58 billion in 2024 to $14.22 billion in 2025, with a compound annual growth rate (CAGR) of 4.7%. The growth experienced during the previous period can be traced back to factors like increased prevalence of diabetes, effective clinical results, heightened patient awareness and acceptance, worldwide health initiatives, and a preference among patients for injectable treatments.

The market size for GLP-1 receptor agonists is projected to witness significant expansion in the coming years, predicted to reach $17.72 billion by 2029, with a compound annual growth rate (CAGR) of 5.7%. The anticipated expansion during the forecast period is ascribed to factors such as increased focus on lifestyle modification, growth in personalized healthcare strategies, broadened diagnostic scopes, the advent of new-age products, and incorporation into combination treatments. The forecast period is further likely to experience several trends including the launch of oral medication forms, emphasis on combined treatment options, strategic alliances and collaborations, policy procedures for reimbursements and accessibility, and patient-oriented approaches.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9631&type=smp

What are the most significant trends transforming the glp-1 receptor agonist market today?
One significant trend gathering momentum in the GLP-1 receptor agonist market is product innovation. Prominent firms in the GLP-1 receptor agonist sector are focusing these efforts to reinforce their standing in the marketplace. An illustration of this trend is presented by Eli Lilly and Company, an American pharmaceutical entity committed to enhancing lives through innovative medication, with the introduction of an FDA-approved new drug, Mounjaro, a GIP and GLP-1 receptor agonist, in May 2022. This drug employs a unique molecule that activates the body's receptors for incretin hormones GIP and GLP-1. This innovative medication is delivered via a pen auto-injector equipped with a non-visible, pre-attached needle, eliminating the need for patients to handle or see it. Moreover, it is offered in 6 different dose options.

Which key market segments comprise the glp-1 receptor agonist market and drive its revenue growth?
The GLP-1 receptor agonist market covered in this report is segmented -

1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
2) By Route Of Administration: Parenteral, Oral
3) By End Users: Hospitals, Surgical Clinics, Other Users

Subsegments:
1) By Exenatide: Byetta, Bydureon
2) By Liraglutide: Victoza, Saxenda
3) By Dulaglutide: Trulicity
4) By Lixisenatide: Adlyxin
5) By Other Drugs: Semaglutide, Tirzepatide, Others

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9631

What regions are at the forefront of glp-1 receptor agonist market expansion?
North America was the largest region in the GLP-1 receptor agonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the GLP-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the leading players fueling growth in the glp-1 receptor agonist market?
Major companies operating in the GLP-1 receptor agonist market include Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=9631&type=smp

What Is Covered In The GLP-1 Receptor Agonist Global Market Report?

• Market Size Forecast: Examine the glp-1 receptor agonist market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the glp-1 receptor agonist market for a structured understanding.
• Key Players Overview: Analyze major players in the glp-1 receptor agonist market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the glp-1 receptor agonist market.
• Segment Contributions: Evaluate how different segments drive overall growth in the glp-1 receptor agonist market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the glp-1 receptor agonist market.
• Industry Challenges: Identify potential risks and obstacles affecting the glp-1 receptor agonist market.
• Competitive Landscape: Review strategic developments in the glp-1 receptor agonist market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.